文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

耐紫杉醇癌细胞中获得性交叉耐药的多样性与通过FOXO3a介导的ABCB1调控对TUBB3的反馈控制有关。

Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation.

作者信息

Aldonza Mark Borris D, Hong Ji-Young, Alinsug Malona V, Song Jayoung, Lee Sang Kook

机构信息

College of Pharmacy, Seoul National University, Seoul 151-742, Korea.

Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul 151-742, Korea.

出版信息

Oncotarget. 2016 Jun 7;7(23):34395-419. doi: 10.18632/oncotarget.9118.

DOI:10.18632/oncotarget.9118
PMID:27284014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5085164/
Abstract

Acquired drug resistance is a primary obstacle for effective cancer therapy. The correlation of point mutations in class III β-tubulin (TUBB3) and the prominent overexpression of ATP-binding cassette P-glycoprotein (ABCB1), a multidrug resistance gene, have been protruding mechanisms of resistance to microtubule disruptors such as paclitaxel (PTX) for many cancers. However, the precise underlying mechanism of the rapid onset of cross-resistance to an array of structurally and functionally unrelated drugs in PTX-resistant cancers has been poorly understood. We determined that our established PTX-resistant cancer cells display ABCB1/ABCC1-associated cross-resistance to chemically different drugs such as 5-fluorouracil, docetaxel, and cisplatin. We found that feedback activation of TUBB3 can be triggered through the FOXO3a-dependent regulation of ABCB1, which resulted in the accentuation of induced PTX resistance and encouraged multiplicity in acquired cross-resistance. FOXO3a-directed regulation of P-glycoprotein (P-gp) function suggests that control of ABCB1 involves methylation-dependent activation. Consistently, transcriptional overexpression or downregulation of FOXO3a directs inhibitor-controlled protease-degradation of TUBB3. The functional PI3K/Akt signaling is tightly responsive to FOXO3a activation alongside doxorubicin treatment, which directs FOXO3a arginine hypermethylation. In addition, we found that secretome factors from PTX-resistant cancer cells with acquired cross-resistance support a P-gp-dependent association in multidrug resistance (MDR) development, which assisted the FOXO3a-mediated control of TUBB3 feedback. The direct silencing of TUBB3 reverses induced multiple cross-resistance, reduces drug-resistant tumor mass, and suppresses the impaired microtubule stability status of PTX-resistant cells with transient cross-resistance. These findings highlight the control of the TUBB3 response to ABCB1 genetic suppressors as a mechanism to reverse the profuse development of multidrug resistance in cancer.

摘要

获得性耐药是有效癌症治疗的主要障碍。III类β-微管蛋白（TUBB3）中的点突变与多药耐药基因ATP结合盒P-糖蛋白（ABCB1）的显著过表达之间的相关性，一直是许多癌症对微管破坏剂（如紫杉醇（PTX））产生耐药性的突出机制。然而，PTX耐药性癌症对一系列结构和功能不相关药物快速产生交叉耐药的确切潜在机制尚不清楚。我们确定，我们建立的PTX耐药癌细胞对化学性质不同的药物（如5-氟尿嘧啶、多西他赛和顺铂）表现出与ABCB1/ABCC1相关的交叉耐药性。我们发现，TUBB3的反馈激活可通过FOXO3a对ABCB1的依赖性调节触发，这导致诱导的PTX耐药性加剧，并促进获得性交叉耐药的多样性。FOXO3a对P-糖蛋白（P-gp）功能的定向调节表明，对ABCB1的控制涉及甲基化依赖性激活。一致地，FOXO3a的转录过表达或下调指导抑制剂控制的TUBB3蛋白酶降解。功能性PI3K/Akt信号通路对FOXO3a激活以及阿霉素治疗有紧密反应，这指导FOXO3a精氨酸高甲基化。此外，我们发现，具有获得性交叉耐药性的PTX耐药癌细胞的分泌组因子在多药耐药（MDR）发展中支持P-gp依赖性关联，这有助于FOXO3a介导的TUBB3反馈控制。TUBB3的直接沉默可逆转诱导的多重交叉耐药性，减少耐药肿瘤块，并抑制具有短暂交叉耐药性的PTX耐药细胞受损的微管稳定性状态。这些发现突出了对TUBB3对ABCB1基因抑制因子反应的控制，作为一种逆转癌症中多药耐药大量发展的机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/f6173290c758/oncotarget-07-34395-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/4ce7480c2d2b/oncotarget-07-34395-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/a03e57b1c431/oncotarget-07-34395-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/c8d2b1603d66/oncotarget-07-34395-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/9bde8a4857ac/oncotarget-07-34395-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/cc5c50a1dee6/oncotarget-07-34395-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/1523b81bd7e7/oncotarget-07-34395-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/3efe4f8e622f/oncotarget-07-34395-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/f6173290c758/oncotarget-07-34395-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/4ce7480c2d2b/oncotarget-07-34395-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/a03e57b1c431/oncotarget-07-34395-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/c8d2b1603d66/oncotarget-07-34395-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/9bde8a4857ac/oncotarget-07-34395-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/cc5c50a1dee6/oncotarget-07-34395-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/1523b81bd7e7/oncotarget-07-34395-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/3efe4f8e622f/oncotarget-07-34395-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c8/5085164/f6173290c758/oncotarget-07-34395-g008.jpg

相似文献

[1]
Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation.

Oncotarget. 2016-6-7

[2]
Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation.

Exp Mol Med. 2017-1-20

[3]
Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells.

Mol Cancer Ther. 2008-3

[4]
Molecular mechanisms of patupilone resistance.

Cancer Res. 2008-12-15

[5]
Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.

Tumour Biol. 2014-9

[6]
Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.

Oncotarget. 2015-12-29

[7]
Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.

Cancer Chemother Pharmacol. 2009-5

[8]
Tangeretin, a citrus pentamethoxyflavone, antagonizes ABCB1-mediated multidrug resistance by inhibiting its transport function.

Pharmacol Res. 2016-4-4

[9]
Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.

Biol Pharm Bull. 2015

[10]
Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.

Oncotarget. 2016-11-8

引用本文的文献

[1]
UGCG promotes chemoresistance and breast cancer progression via NF-κB and Wnt/β-catenin pathway activation.

Transl Oncol. 2025-2

[2]
Mechanisms of Resistance to Antibody-Drug Conjugates.

Cancers (Basel). 2023-2-17

[3]
Antibody-drug conjugates in lung cancer: dawn of a new era?

NPJ Precis Oncol. 2023-1-11

[4]
Combination of Paclitaxel and PXR Antagonist SPA70 Reverses Paclitaxel-Resistant Non-Small Cell Lung Cancer.

Cells. 2022-10-1

[5]
An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer.

Mol Cancer. 2022-4-27

[6]
Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles.

Cancers (Basel). 2021-11-12

[7]
Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms.

Sci Adv. 2020-2-7

[8]
RILPL2 regulates breast cancer proliferation, metastasis, and chemoresistance via the TUBB3/PTEN pathway.

Am J Cancer Res. 2019-8-1

[9]
Optimization Of Cancer Treatment Through Overcoming Drug Resistance.

J Cancer Res Oncobiol. 2018

[10]
Substituents at the C3' and C3'N positions are critical for taxanes to overcome acquired resistance of cancer cells to paclitaxel.

Toxicol Appl Pharmacol. 2018-4-4

本文引用的文献

[1]
Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer Cells.

PLoS One. 2015-6-22

[2]
Antitumor activity of phenanthroindolizidine alkaloids is associated with negative regulation of Met endosomal signaling in renal cancer cells.

Chem Biol. 2015-4-23

[3]
Therapy-induced tumour secretomes promote resistance and tumour progression.

Nature. 2015-4-16

[4]
Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.

Oncotarget. 2015-4-30

[5]
Investigation of Paclitaxel Resistant R306C Mutation in β-Tubulin—A Computational Approach.

J Cell Biochem. 2015-7

[6]
Stanniocalcin-2 (STC2): A potential lung cancer biomarker promotes lung cancer metastasis and progression.

Biochim Biophys Acta. 2015-6

[7]
Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance.

Curr Drug Targets. 2016

[8]
Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance.

BMC Cancer. 2014-10-14

[9]
How Taxol/paclitaxel kills cancer cells.

Mol Biol Cell. 2014-9-15

[10]
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.

Cancer Cell. 2014-7-24

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索